ESC 365 - Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy

HFA Premium Access

Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy

Session: Young Investigator Award: clinical research

Topic: Hypertrophic Cardiomyopathy

Speaker: Doctor R. Rettl (Vienna, AT)

Event: Heart Failure 2021

Congress Presentation

Add to my library

About the speaker

Doctor Rene Rettl

Medical University of Vienna, Vienna (Austria)

0 follower

3 more presentations in this session

Effect of SGLT2 inhibitors on diastolic function in patients with non-obstructive hypertrophic cardiomyopathy

Speaker: Doctor M. Subramanian (Hyderabad, IN)

Efficacy of additional medical therapies in patients with heart failure, a reduced ejection fraction and chronic kidney disease already receiving neurohormonal inhibitors: a network meta-analysis

Speaker: Doctor V. De Marzo (Genoa, IT)

Target dose of heart failure medications is associated with better mortality/morbidity: data from the Swedish Heart Failure Registry

Speaker: Mr D. Rodolico (Pisa, IT)

Access the full session

Young Investigator Award: clinical research

Speakers: Doctor R. Rettl, Doctor M. Subramanian, Doctor V. De Marzo, Mr D. Rodolico

About the event

Heart Failure 2021

29 June - 1 July 2021

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources